icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
MBvRu44km8jUPKcB